Potential roles of vitamin D binding protein in attenuating liver injury in sepsis

Kun Xiao1†, Du-Chao Zhang2†, Ye Hu1, Li-Cheng Song1, Jian-Qiao Xu1, Wan-Xue He3, Pan Pan1, Yu-Wei Wang4* and Li-Xin Xie1*

Abstract
Background: In sepsis, vitamin D binding protein (VDBP) has been shown to be low-expressed. The current study examined the relationship between serum VDBP level and liver injury in sepsis patients, as well as in a mouse model for sepsis and in cultured liver epithelial cell line exposed to lipopolysaccharide (LPS).

Methods: The human study included 78 sepsis patients and 50 healthy volunteers. Sepsis patients were categorized into sepsis survivor group (n = 43) and sepsis non-survivor group (n = 35) based on 28-day mortality for data analysis. Adult male C57BL/6 mice were subjected to cecal ligation and puncture (CLP). Serum samples were collected on day 1, 3, 5 and 7 to determine the levels of VDBP, 25-hydroxyvitamin D [25(OH)D3], 1,25-dihydroxyvitamin D [1,25(OH)2D3], interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α). Potential protective effects of VDBP overexpression against LPS-induced liver damage were examined in cultured THLE2 cells.

Results: Serum levels of VDBP, 25(OH)D3, and 1,25(OH)2D3 were significantly lower in sepsis patients vs. the healthy control (P < 0.001), as well as in the sepsis non-survivor group vs. the sepsis survivor group (P = 0.0338, or P = 0.0013, respectively). Lower serum VDBP level was associated with higher Acute Physiology and Chronic Health Evaluation (APACHE) II score (r = −0.2565, P = 0.0234) and Sequential Organ Failure Assessment score (r = −0.3522, P = 0.0016), but lower serum albumin (ALB, r = 0.4628, P < 0.001) and total protein (TP, r = 0.263, P = 0.02). In CLP mice, there was a 5-day period of serum VDBP reduction, followed by return towards the baseline on day 7. VDBP was also decreased in LPS-treated THLE2 cells (P < 0.001). VDBP overexpression reduced LPS-induced THLE2 damage. Reduced damage was associated with decreased oxidative stress and inactivation of the c-Jun N-terminal kinase signaling pathway.

Conclusion: VDBP may be protective against sepsis-induced liver injury.

Keywords: Vitamin D binding protein, Sepsis, Human, Mouse, Liver, Injury, JNK

Introduction
Sepsis is a major health threat with an incidence of 45 per 10,000 people and approximately 20% mortality [1–3]. Sepsis can be caused by a variety of pathogens, including bacteria, viruses, fungi and parasites, and is characterized by excessive inflammation, immune suppression and systemic activation of coagulation [4–6]. Despite significant advances in the management of sepsis in the past decades, there have been no unifying diagnostic criteria and standard treatments [6–8].
Vitamin D binding protein (VDBP), also known as Gc-globulin, is encoded by the group-specific component (GC) gene [9]. VDBP is essential for the binding, solubilization, and transport of vitamin D and metabolites, including 25-hydroxyvitamin D [25(OH)D3] (the major form in circulation) and 1,25-dihydroxyvitamin D [1,25(OH)2D3] (the active form) [10]. VDBP has been implicated in the regulation of a variety of pathophysiological processes, including chemotaxis, bone metabolism, and inflammatory responses [11, 12]. Previous studies showed lower VDBP plasma levels in sepsis patients than in healthy volunteers [10, 13]. Also, lower level of circulating VDBP in sepsis patients has been associated with more severe disease [14] and increased mortality [15].

Multiple organ failure is a common feature in sepsis patients [6, 16, 17]. VDBP plasma level has been found to be lower in patients who developed multiple organ failure and sepsis after traumatic injury compared with patients who did not [18]. Serum VDBP concentration also has been shown to be increased in most patients undergoing liver transplantation [19], supporting a role of VDBP in liver damage and recovery. In the current study, we first examined the relationship between VDBP level and liver damage in sepsis patients, and then conducted a series of experiments in cultured liver epithelial cells and a mouse model for sepsis to examine the potential mechanisms.

Methods

Clinical investigation

Study protocol was approved by the Ethics Committee of the Chinese People’s Liberation Army (PLA) General Hospital (S2015-069-01). All subjects provided written informed consents. Adult patients with sepsis (n = 78) were recruited from the intensive care unit (ICU) of the Chinese PLA General Hospital between May 2016 and May 2018. Sepsis was defined using the Sepsis 3.0 Diagnostic Criteria [1]. Patients were categorized into two groups based on 28-day mortality [20]: sepsis survivor group [sepsis (s), n = 43] and sepsis non-survivor group [sepsis (d), n = 35]. Healthy adult volunteers (n = 50) were recruited from the Physical Examination Center of the Chinese PLA General Hospital between March 2017 and May 2018. Subjects (either patients or healthy volunteers) with malignancies or human immunodeficiency virus were excluded. Sepsis patients who died within 24 h of diagnosis or received immunosuppressive therapy were also excluded. Serum samples were kept at -80 °C prior to analysis.

Human VDBP, 25(OH)D3, and 1,25(OH)2D3 serum levels were determined using matching enzyme-linked immunosorbent assay (ELISA) commercial kits and manufacturer procedures. Human VDBP, 25(OH)D3, and 1,25(OH)2D3 ELISA detection kits were acquired from Abcam (cat. no. ab223586, Cambridge, UK), Immunodiagnostic Systems (cat. No. AC-57F1, IDS, Boldon, UK), and TSZ Biosciences (Framingham, MA, USA), respectively.

Animal experiments

The study protocol was approved by the Animal Ethics Committee of the Chinese PLA General Hospital (2014-X9-16). A total of 40 adult male C57BL/6 mice (6 weeks of age; Beijing Vital River Laboratory Animal Technology, Beijing, China) were randomly divided into sham group (n = 20) and cecal ligation and puncture (CLP) group (n = 20). Five mice were included at each time point (day 1, 3, 5, 7) after surgery in sham or CLP group. Mice in the CLP group were subjected to CLP treatment as previously described [21, 22]. Briefly, mice were anesthetized intraperitoneally with a combination of Su mianxin injection (Fujian Jitian Pharmaceutical Co. Ltd., Xiamen, China), ketamine injection (Fujian Jitian Pharmaceutical Co. Ltd.) and normal saline (volume ratio = 2:1.5:3.5, 50 μl/mouse). A midline abdominal incision (1.5–2.0 cm) was made. The cecum was ligated with sterile silk sutures from the two-thirds location of the cecum end (2/3 ligation), pierced twice with an 8-gauge needle, and squeezed lightly to force intestinal content into the peritoneal cavity before closing the incision. A group of mice undergoing a sham procedure (identical anesthesia and surgical maneuver but no ligation and puncture of the cecum) and identical sampling scheme were included as control. All mice received a subcutaneous injection of pre-warm normal saline (0.05 ml/g body weight) after CLP or sham surgery.

Serum VDBP (cat. no. DY4188-05), interleukin-6 (IL-6, cat. no. M6000B) and tumor necrosis factor alpha (TNF-α, cat. no. MTA00B) were determined using ELISA kits from R&D Systems (Minneapolis, MN, USA). The right liver lobe was fixed in 10% formaldehyde, embedded in paraffin wax, and sliced for hematoxylin–eosin (HE) staining using a standard protocol. For immunohistochemistry (IHC), tissue slices were quenched with 3% H2O2, followed by antigen retrieving. Slices were blocked with 10% goat serum for 1 h before being incubated with a primary antibody against VDBP (1:200 dilution, cat. no. ab153922, Abcam, Cambridge, UK) for 2 h at 37 °C. Following incubation with an appropriate secondary antibody, staining was visualized with 3,3′-diaminobenzidine (DAB) substrate (Thermo Fisher Scientific) and counterstained with hematoxylin. Images were acquired using an Olympus BH2 microscope (Olympus, Center Valley, Pennsylvania, USA), and analyzed using an Image-Pro Plus 6.0 software (Media Cybernetics, Silver Spring, MD, USA).
USA). The left liver lobe was used for Western blotting and RNA analysis.

**Cell culture and reagents**

Transformed human liver epithelial cell line (THLE2) was obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured in BEGM basal medium supplemented with 5 ng/ml epidermal growth factor (EGF), 70 ng/ml phosphoethanolamine, and 10% fetal bovine serum (CC3170-BEGM Bullet Kit, Lonza Corporation, Walkersville, MD, USA) at 37 °C in a humidified incubator containing 5% CO₂. Recombinant lentiviruses encoding the human VDBP (LV-VDBP) and control (LV-NC) were designed by Hanbio Biotechnology (Shanghai, China).

**Caspase-3/9 activity and oxidative stress**

Caspase-3 (cat. no. C1116) and caspase-9 (cat. no. C1158) activity was determined using kits from Beyotime Biotechnology (Shanghai, China). Myeloperoxidase (MPO) activity was measured using a kit (cat. no. ab105136) from Abcam. Malondialdehyde (MDA) level was determined using a kit (cat. no. S0131S) from Beyotime Biotechnology. Glutathione (GSH) level was determined using a kit (cat. no. CS0260) from Sigma-Aldrich (St. Louis, MO, USA).

**Reverse transcription-quantitative PCR (RT-qPCR) assay**

Total RNA was isolated from tissue samples or cultured cells using the RNAprep Pure Animal Tissue Total RNA Extraction Kit (Tiangen Biotech, Beijing, China) or the Trizol reagent (Thermo Fisher Scientific), respectively. A Fast Quant cDNA first strand synthesis kit (Tiangen Biotech) was used to create the cDNA first strand. RT-PCR experiment was conducted in triplicate using the KAPA SYBR FAST qPCR Kit (KAPA Biosystems, Wilmington, DE, USA). Primer sequences were: 5′-GCTGACCTT GACTGCTGTATGAC-3′ (forward) and 5′-CATGCA GAGCTTTGGTTC-3′ (reverse) for human VDBP; 5′-AGCCCTAGATCAGCAGCAA GCC-3′ (forward) and 5′-TGTGGTCATGAGTCCCTCCAGAT-3′ (reverse) for human GAPDH.

**Western blotting assay**

Tissue samples and cells were lysed with pre-cold RIPA lysis solution (Beijing Apphysen Technologies) in a glass homogenizer, and centrifuged at 12,000 g for 10 min. Protein concentration was measured using a BCA kit (Thermo Fisher Scientific). Proteins (35 μg/sample) were separated using polyacrylamide gel electrophoresis with 10% sodium dodecyl sulfate and transferred to polyvinylidene difluoride membranes (Millipore, Darmstadt, Germany). The membranes were blocked with 5% nonfat milk prior to overnight incubation at 4 °C with a primary antibody against VDBP (1:5000 dilution, cat. no. ab81307, Abcam), c-Jun N-terminal kinase (JNK) (1:1000 dilution, cat. no. #9252, Cell Signaling Technology), or phospho-rylated JNK (p-JNK) (1:2000 dilution, cat. no. #9255, Cell Signaling Technology). The membranes were then incubated with an appropriate horseradish peroxidase (HRP)-labeled secondary antibody (Zhongshan Jinqiao Biotechnology) for 1 h. Protein bands of interest were visualized using an ECL kit (Thermo Fisher Scientific).

**Cell viability**

Cells (10⁴/well) in logarithmic growth phase were plated in 96-well plates. Cells were exposed to lipopolysaccharide (LPS) (Sigma-Aldrich, St. Louis, MO, USA) for 24 h, and 90 μl of fresh media and 10 μl of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 5 mg/ml) solution were added to each well. After 4 h, the medium was aspirated and 180 μl dimethylsulphoxide (DMSO) was added to each well for 10 min to dissolve the generated formazan complexes. Absorbance was measured at 492 nm.

**Apoptosis**

Apoptosis was examined using flow cytometry (BD Biosciences) with the FITC Annexin V Apoptosis Detection Kit (BD Biosciences, Franklin Lakes, NJ, USA).

**Alanine aminotransferase (ALT) and aspartate transaminase (AST) activity determination**

ALT and AST activity was determined using kits (ab105134, ab105135) from Abcam.

**Statistical analysis**

GraphPad Prism software (La Jolla, CA, USA) was used to analyze the data. Continuous variables are reported as means ± standard deviation (SD), and analyzed using Student’s t-test (for two-group data) or one-way ANOVA followed by Tukey’s test for post hoc pairwise comparison. Statistical significance was set at P < 0.05.

**Results**

Serum VDBP, 25(OH)D₃, and 1,25(OH)₂D₃ were lower in sepsis patients than healthy controls

In comparison to the healthy control group, serum VDBP, 25(OH)D₃, and 1,25(OH)₂D₃ levels were significantly lower in sepsis survivor group [VDBP: (418.06 ± 64.26) μg/ml vs. (295.20 ± 52.90) μg/ml, P < 0.001; 25(OH)D₃: (112.30 ± 23.70) nmol/L vs. (26.20 ± 12.70) nmol/L, P < 0.001; 1,25(OH)₂D₃: (21,706.50 ± 3331.60) fmol/L vs. (8106.00 ± 2952.10) fmol/L, P < 0.001] and sepsis non-survivor group [VDBP: (418.06 ± 64.26) vs. (178.10 ± 30.60) μg/ml, P < 0.001;
25(OH)D$_3$: (112.30 ± 23.70) nmol/L vs. (19.60 ± 12.60) nmol/L, \(P < 0.001\); 1,25(OH)$_2$D$_3$: (21,706.50 ± 3331.60) fmol/L vs. (5852.70 ± 1040.40) fmol/L, \(P < 0.001\) (Fig. 1a–c). Serum VDBP, 25(OH)D$_3$, and 1,25(OH)$_2$D$_3$ levels in the sepsis survivor group were higher than in the sepsis non-survivor group [VDBP: (295.20 ± 52.90) μg/ml vs. (178.10 ± 30.60) μg/ml, \(P < 0.001\); 25(OH)D$_3$: (26.20 ± 12.70) nmol/L vs. (19.60 ± 12.60) nmol/L, \(P = 0.0338\); 1,25(OH)$_2$D$_3$: (8106.00 ± 2952.10) fmol/L vs. (5852.70 ± 1040.40) fmol/L, \(P = 0.0013\)] (Fig. 1a–c).

A correlation analysis in the sepsis patients showed an association between higher VDBP with higher 25(OH)D$_3$ serum level (\(r = 0.609, P < 0.001\)) but not with 1,25(OH)$_2$D$_3$ level (\(r = 0.1485, P = 0.194\)) (Fig. 1d, e). Serum 1,25(OH)$_2$D$_3$ did not correlate with 25(OH)D$_3$ in sepsis patients (\(r = -0.1087, P = 0.344\)) (Fig. 1f). The demographic and clinical characteristics of sepsis patients in the survivor [sepsis (s), \(n = 43\)] vs. non-survivor [sepsis (d), \(n = 35\)] group were shown in Table 1.

**Association of low VDBP level with disease severity and liver injury**

The severity of sepsis was assessed by Acute Physiology and Chronic Health Evaluation (APACHE) II and SOFA scores given their independent correlations with hospital mortality in sepsis patients [20, 23]. In sepsis patients, lower serum VDBP level was associated with more severe disease, as evidenced by higher APACHE II score (\(r = -0.2565, P = 0.0234\)) and SOFA score (\(r = -0.3522, P = 0.0016\)) (Fig. 2a, b). Lower serum VDBP level was associated with lower albumin (ALB; \(r = 0.4628, P < 0.001\), Fig. 2c) and total protein (TP; \(r = 0.263, P = 0.02\), Fig. 2d).

**Temporal profile of serum VDBP in CLP mice**

Starting from 12 h following surgery, mice in the CLP group displayed signs suggestive of sepsis, including lethargy and fever. Serum VDBP level started to decrease on day 1, reached a nadir on day 5, and returned to baseline level on day 7 (Fig. 3a). Serum levels of IL-6 (Fig. 3b) and TNF-α (Fig. 3c) both peaked on day 1. Only 30% of the mice in the CLP group survived beyond day 5 (Fig. 3d).

**Low VDBP expression in the liver of CLP mice**

HE staining revealed robust liver damage (e.g. vascular rupture, hemorrhage, hepatocyte edema, abnormalities in hepatocyte distribution and hepatic sinusoid structure) and inflammatory cell infiltration in CLP mice (Fig. 4a). Similar to the temporal pattern of serum VDBP, the extent of liver damage reached a plateau on day 5 (Fig. 4a). IHC test showed lower VDBP levels in the liver tissues of CLP mice vs. sham mice (\(P < 0.001\), Fig. 4b). VDBP level in the liver of CLP mice was the lowest on day 3, and then gradually increased towards the baseline (Fig. 4b).

**Experiments in THLE2 cells exposed to LPS**

LPS decreased the viability of THLE2 liver cells in a time-dependent manner (Fig. 5a). Effects of LPS were...
also concentration-dependent at a range between 10 and 10 μg/ml (Fig. 5b). Subsequent experiments using 1 μg/ml LPS for 24 h revealed reduced VDBP mRNA 
\( (P < 0.001) \), protein, as well as secretion into the supernatant 
\( (P < 0.001) \), Fig. 5c). In addition to decreased cell viability 
\( (P < 0.001) \), LPS exposure increased the rate of apoptotic cells, caspase-3 activity 
\( (P < 0.001) \), caspase-9 activity 
\( (P < 0.001) \) (Fig. 5d), as well as the level of ALT 
\( (P < 0.001) \) and AST 
\( (P < 0.001) \) in supernatant (Fig. 5e).

These findings showed that the LPS-induced liver cell damage model had been created successfully. Moreover, MPO activity and MDA level were increased 
\( (P < 0.001) \), and GSH level was decreased 
\( (P < 0.001) \) following LPS treatment (Fig. 5f).

### Table 1 Clinical information about sepsis patients in the survivor and non-survivor groups

| Clinical data               | Sepsis survivor group \( (n = 43) \) | Sepsis non-survivor group \( (n = 35) \) | \( P \)  |
|-----------------------------|--------------------------------------|---------------------------------------|--------|
| Age (year, mean ± SD)       | 49.7 ± 22.0                          | 71.6 ± 14.4                           | <0.001 |
| Gender (male/female)        | 29/14                                | 27/8                                  | >0.05  |
| WBC \( (\times 10^9/L, \text{mean} \pm SD) \) | 13.6 ± 6.0                           | 13.1 ± 6.9                            | >0.05  |
| CRP (mg/dl, mean ± SD)      | 11.1 ± 7.7                           | 10.1 ± 6.3                            | >0.05  |
| Ca\(^{2+}\) (mmol/L, mean ± SD) | 2.077 ± 0.261                       | 2.012 ± 0.268                        | >0.05  |
| TP (g/L, mean ± SD)         | 56.457 ± 13.521                      | 54.963 ± 10.155                       | >0.05  |
| PHOS (mmol/L, mean ± SD)    | 0.949 ± 0.357                        | 0.993 ± 0.619                         | >0.05  |
| ALB (g/L, mean ± SD)        | 30.9 ± 8.2                           | 30.3 ± 5.5                            | >0.05  |
| SOFA score (mean ± SD)      | 5.5 ± 3.7                            | 10.7 ± 7.3                            | <0.001 |
| APACHE II score (mean ± SD) | 15.6 ± 6.3                           | 24.9 ± 7.4                            | <0.001 |
| VDBP (μg/ml, mean ± SD)     | 295.2 ± 52.9                         | 178.1 ± 30.6                          | <0.001 |
| 25(OH)D\(_3\) (μmol/L, mean ± SD) | 26.2 ± 12.7                         | 19.6 ± 12.6                           | 0.0247 |
| 1,25(OH)\(_2\)D\(_3\) (fmol/L, mean ± SD) | 8106.0 ± 4952.1                     | 5852.7 ± 2040.4                       | 0.0138 |

ALB: albumin; APACHE: Acute Physiology and Chronic Health Evaluation; CRP: C reactive protein; PHOS: phosphorus; SOFA: Sequential Organ Failure Assessment; TP: total protein; VDBP: vitamin D binding protein; WBC: white blood cell.

**Fig. 2** Association of VDBP level with disease severity and liver injury.  
\( a, b \) Correlation analysis between VDBP serum level and APACHE II \( (P < 0.05) \) or SOFA score \( (P < 0.01) \) of sepsis patients \( (n = 78) \).  
\( c, d \) Bivariate correlation analysis between VDBP serum level and ALB level \( (P < 0.001) \) or TP level \( (P < 0.05) \) in sepsis patients \( (n = 78) \).  
ALB: albumin; APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; TP: total protein; VDBP: vitamin D binding protein.

**Fig. 3** Expression analysis of VDBP and inflammatory factors in serum samples of sham mice and CLP mice. Mice \( (n = 40) \) were randomly divided into sham group \( (n = 20) \) and CLP group \( (n = 20) \). Five mice were included at each time point \( (day 1, 3, 5, 7) \) after surgery in sham or CLP group.  
\( a \) Mouse VDBP level in serum samples was detected in sham and CLP mice at the indicated time points \( (day 0, 1, 3, 5, 7) \) after surgery by mouse VDBP ELISA kit.  
\( b, c \) Mouse IL-6 and TNF-α serum levels were detected in sham and CLP mice at the indicated time points \( (day 0, 1, 3, 5, 7) \) after surgery by mouse IL-6 or TNF-α ELISA kit, respectively.  
\( d \) Survival rate of sham and CLP mice. Compared with sham group, **\( P < 0.01 \) and ***\( P < 0.001 \).  
CLP: cecal ligation and puncture; IL-6: interleukin 6; TNF-α: tumor necrosis factor alpha; VDBP: vitamin D binding protein.
VDBP overexpression using a lentiviral vector attenuated the effects of LPS exposure on cell viability ($P = 0.0239$), apoptosis, caspase-3 activity ($P = 0.0115$) and caspase-9 activity ($P = 0.0159$) (Fig. 5d). VDBP expression also markedly reduced LPS-induced ALT ($P = 0.0098$) and AST ($P = 0.0013$) release (Fig. 5e). VDBP overexpression also attenuated the effects of LPS exposure on MPO activity ($P = 0.0045$), MDA level ($P < 0.001$) and GSH level ($P = 0.0043$) (Fig. 5f). LPS exposure resulted in a significant increase in p-JNK protein level in THLE2 cells, and VDBP overexpression inhibited such a response (Fig. 5g).

**Discussion**

Vitamin D (VitD) participates in a variety of biological processes, including bone metabolism, immunomodulation, inflammatory responses, and cell proliferation [24, 25]. VitD deficiency has been linked to a variety of illnesses, including cardiovascular, autoimmune, and infectious diseases [26, 27]. For instance, the most of burn and critically ill patients were VitD deficient, and low level of VitD was associated with poor clinical outcomes (e.g. sepsis, organ failure, and death) following major burn injury and critical illness [6, 28]. VitD is metabolized in the liver first to 25(OH)D$_3$, and then converted to the active 1,25(OH)$_2$D$_3$ in the kidneys [27, 29, 30]. Previous studies suggested high rate of VitD insufficiency in sepsis patients as well as increased risk of sepsis and poor prognosis in subjects with VitD insufficiency [31, 32]. A recent case report of a patient with severe ankylosing spondylitis who did not react to VitD supplementation [9] showed severe VDBP deficiency, and consequently, a significant decrease in VitD-responsive CYP24A1 and VitD metabolites such as 25(OH)D$_3$ and 1,25(OH)$_2$D$_3$, due to homozygous deletion of the GC gene.

Similar to previous studies [10, 13], the current study showed lower serum VDBP as well as lower serum levels of 25(OH)D$_3$ and 1,25(OH)$_2$D$_3$ in sepsis patients vs. the healthy control. Indeed, low 25(OH)D$_3$ plasma level has been shown to be a risk for sepsis [33]. Also, similar
Fig. 5 (See legend on next page.)
to previous studies [34, 35], we also found lower serum levels of VDBP, 25(OH)D$_3$, and 1,25(OH)$_2$D$_3$ in sepsis patients who did not survive beyond 28 days versus survivors.

Organ failure, particularly the liver failure, is associated with poor prognosis in sepsis patients [16, 17]. VDBP serum level has been found to be significantly lower in patients with acute liver failure or chronic hepatitis B [36, 37]. Several studies have also reported lower serum VDBP levels in patients with hepatic fibrosis and an association of the magnitude of VBP reduction with the degree of fibrosis [38, 39]. A previous study in patients undergoing liver transplantation found biphasic change in serum VDBP: an initial decrease and then return to near-normal levels [19]. Altogether, these findings suggested that a role of VDBP in liver damage and regeneration. In the current study, lower serum level of VDBP was associated with abnormality in liver function indexes (ALB and TP) in sepsis patients, suggesting that the alteration of VDBP level was related to liver dysfunction.

Experiments in CLP mice in our study showed a decrease of serum level of VDBP during the first 5 days after the procedure, followed by return towards a near-normal level on day 7. We also found decreased VDBP expression and secretion levels were significantly increased upon LPS exposure. Overexpression of VDBP using a lentiviral vector reduced LPS-induced damage and LPS-mediated oxidative stress. The JNK signaling pathway has been implicated in a variety of biological activities, including cell survival, apoptosis, and responses to intracellular and extracellular stressors (e.g. oxidative and inflammatory stress) [43, 44]. The JNK signaling pathway has also been implicated in liver damage caused by intracellular and extracellular stressors [45]. Puerarin, for example, has been shown to reduce LPS-induced liver damage by inactivating the JNK signaling pathway [46]. Inhibiting the JNK pathway with nobiletin protects liver tissues and cultured hepatocytes against inflammatory stimuli-induced acute damage [47]. Reduced oxidative stress and inactivation of the JNK signaling pathway by VDBP overexpression in the current study suggested involvement of the JNK pathway in sepsis-induced liver damage.

Conclusion

In summary, the current study confirmed lower serum VDBP levels in sepsis patients vs. the healthy control. We also found lower serum VDBP levels in sepsis patients who did not survive beyond 28 days versus those who survived. Sepsis patients with lower VDBP serum level had lower ALB and TP, as well as higher APACHE II and SOFA scores, suggesting the negative association of VDBP level and sepsis disease severity. Moreover, VDBP level was reduced in injured livers of sepsis mice and LPS-induced damaged liver cells. Additionally, VDBP overexpression alleviated LPS-induced liver cell injury, which was associated with the reduction of oxidative stress and inactivation of the JNK signaling pathway. However, our experimental methodology was rudimentary, and more research was required to confirm our findings. Animal investigations...
are needed to examine the impact of VDBP overexpression or knockdown on liver damage and sepsis outcomes, as well as associated molecular processes.

Abbreviations
1,25(OH)₂D₃: 1,25-Dihydroxyvitamin D; 25(OH)D₃: 25-Hydroxyvitamin D; ALT: Alanine aminotransferase; APACHE: Acute physiology and chronic health evaluation; AST: Aspartate transaminase; ATCC: American type culture collection; CLP: Cecal ligation and puncture; DAB: 3,3'-Diaminobenzidine; DMSO: Dimethylsulfoxide; ELISA: Enzyme-Linked Immunosorbent Assay; GC: Group-specific component; GSH: Glutathione; HE: Hematoxylin-eosin; HRP: Horseradish peroxidase; ICU: Intensive Care Unit; IHC: Immunohistochemistry; IL-6: Interleukin-6; TNF-α: Tumor necrosis factor alpha; JNK: C-Jun N-terminal kinase; LPS: Lipopolysaccharide; MDA: Malondialdehyde; MPO: Myeloperoxidase; p-JNK: Phosphorylated JNK; PLA: People’s Liberation Army; RT-qPCR: Reverse transcription-quantitative PCR; SOFA: Sequential Organ Failure Assessment; THLE2: Transformed human liver epithelial cell line; WDD: Vitamin D; VDBP: Vitamin D binding protein.

Acknowledgements
Not applicable.

Authors’ contributions
KX and DCZ designed and performed the experiments. KX wrote the manuscript. YH, LCS, and JQX contributed to the experiment. WXH, PP and KX designed the experiments and revised the manuscript. All authors have read and approved the final manuscript.

Funding
This research was supported by the Clinical Research Support Fund of Chinese PLA General Hospital (2018FC-WJZX-1-03), Youth Talents Promotion Project of China (17-JCJQ-QT-036), and Natural Science Foundation of Beijing (7214254).

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
All procedures performed in studies involving human participants were approved by the Research Ethics Committee of the Chinese PLA General Hospital (2018FC-WJZX-1-03), and in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. All animal experiments were approved by the Animal Ethics Committee of the Chinese PLA General Hospital (2018FC-WJZX-1-03), and in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. All animal experiments were approved by the Animal Ethics Committee of the Chinese PLA General Hospital (2018FC-WJZX-1-03), and in accordance with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Consent for publication
Not applicable.

Competing interests
The authors have no conflict of interest to declare.

Author details
1 Center of Pulmonary and Critical Care Medicine, Chinese People’s Liberation Army (PLA) General Hospital, No. 28, Fuxing Street, Haidian District, Beijing 100853, China. 2 Department of Pulmonary and Critical Care Medicine, Beijing Shijitan Hospital, Beijing 100071, China. 3 Medical School of Chinese People’s Liberation Army (PLA) General Hospital, Beijing 100853, China. 4 Department of Geriatric Comprehensive Surgery, The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, No. 28, Fuxing Street, Haidian District, Beijing 100853, China.

Received: 24 May 2021 Accepted: 4 January 2022 Published online: 20 January 2022

References
1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.
2. Fleschmann C, Scherag A, Adhikari NK, Hartog CS, Tsaganos T, Schlattmann P, et al. Assessment of global incidence and mortality of hospital-treated sepsis: current estimates and limitations. Am J Respir Crit Care Med. 2016;193(3):259–72.
3. Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39(5):517–28.
4. Van Der Poll T, Van De Veerdonk FL, Siciluna BP, Netea MG. The immunopathology of sepsis and potential therapeutic targets. Nat Rev Immunol. 2017;17(7):407–20.
5. Levi M, Van Der Poll T. Coagulopathy and sepsis. Thromb Res. 2017;149:38–44.
6. Zhang P, Zou B, Liu YC, Huang C. The pathogenesis and diagnosis of sepsis post burn injury. Burns Trauma. 2021;9:100047.
7. Rello J, Valenzuela-Sánchez F, Ruiz-Rodríguez M, Moyano S. Sepsis: a review of advances in management. Adv Ther. 2017;34(11):2393–411.
8. Van Engelen T, Wiersinga WJ, Siciluna BP, Van Der Poll T. Biomarkers in sepsis. Crit Care Clin. 2018;34(1):139–52.
9. Hollis BW. Vitamin D-binding protein deficiency and homozygous deletion of the GC gene. N Engl J Med. 2019;380(26):2583–4.
10. Hong K, Florkowski CM, Doogue MP, Bider PA, Lewis, K. G. A monoclonal antibody sandwich ELISA for vitamin D-binding protein (VDBP) is unaffected by GC-globulin phenotype peptides and actin and demonstrates reduced levels in sepsis and non-sepsis intensive care patients. Clin Chim Acta. 2018;484:7–13.
11. Delanghe JR, Yamshchikov AV, Judd SE, Blumberg HM, Martin GS, Ziegler TR, et al. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med. 2009;7:28.
12. Horváth-Száli Z, Kustán P, Sármay B, Lakatos Á, Lakatos Á, Zádor J, et al. Predictive value of serum gelisolin and Gc globulin in sepsis: a pilot study. Clin Chem Lab Med. 2018;56(8):1373–82.
13. Del Pinto R, Ferri C, Cominelli F. Vitamin D axis in inflammatory bowel diseases: role, current uses and future perspectives. Int J Mol Sci. 2017;18(11):2360.
14. Peng L, Qian X, Li X, Wang L, Li Y, et al. The GC gene. N Engl J Med. 2019;380(26):2583–4.
15. Pool R, Gomez H, Callum JM, Martin GS, Ziegler TR, et al. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med. 2009;7:28.
16. Horváth-Száli Z, Kustán P, Sármay B, Lakatos Á, Christensen PH, Huber T, et al. Predictive value of serum gelisolin and Gc globulin in sepsis: a pilot study. Clin Chem Lab Med. 2018;56(8):1373–82.
17. Suberviola B, Lavin BA, Jimenez AF, Perez-San Martin S, Garcia-Urzueta M, Santibáñez M. Vitamin D binding protein, but not vitamin D or vitamin D-related peptides, is associated with septic shock mortality. Enferm Infeccc Microbiol Clin (Engl Ed). 2019;37(4):239–43.
18. Pool R, Gomez H, Kellum JA. Mechanisms of organ dysfunction in sepsis. Crit Care Clin. 2018;34(1):63–80.
19. Caraballo C, James F. Organ dysfunction in sepsis: an ominous trajectory from infection to death. Yale J Biol Med. 2019;92(4):629–40.
20. Dahl B, Schrodt FV, Ott P, Wans P, Lee WM, Balko J, et al. Plasma concentration of Gc-globulin is associated with organ dysfunction and sepsis after injury. Crit Care Med. 2003;31(11):152–6.
21. Schrodt FV, Bondelesen S, Müller K, Rasmussen A, Hjortrup A, Kirkegaard P, et al. Reconstitution of the actin-scavenger system after orthotopic liver transplantation for end-stage liver disease: a prospective and longitudinal study. Liver Transpl Surg. 1999;5(4):310–7.
22. Liu S, Li Y, She F, Zhao X, Yao Y. Predictive value of immune cell counts and neutrophil-to-lymphocyte ratio for 28-day mortality in patients with sepsis caused by intra-abdominal infection. Burns Trauma. 2021;9:100040.
23. Gao YL, Chi YF, Dong N, Han S, Zhu XM, Zhang QH, et al. Tuftsin-derived T-peptide prevents cellular immunosuppression and improves survival rate in septic mice. Sci Rep. 2015;5:16725.
24. Patel A, Joseph J, Periasamy H, Mokale S. Azithromycin in combination with ceftriaxone reduces systemic inflammation and provides survival benefit in a murine model of polymicrobial sepsis. Antimicrob Agents Chemother. 2018;62(9):e00752-e018.
25. Li W, Wang M, Zhu B, Zhu Y, Xi X. Prediction of median survival time in sepsis patients by the SOFA score combined with different predictors. Burns Trauma. 2020;8:tk006.
26. Czaja AJ, Montano-Loza AJ. Evolving role of Vitamin D in immune-mediated disease and its implications in autoimmune hepatitis. Dig Dis Sci. 2019;64(2):324–44.
25. Anderson PH. Vitamin D activity and metabolism in bone. Curr Osteoporos Rep. 2017;15(5):443–9.
26. Taylor CL, Sempos CT, Davis CD, Brannon PM. Vitamin D: moving forward to address emerging science. Nutrients. 2017;9(12):1308.
27. Holick MF. The vitamin D deficiency pandemic: approaches for diagnosis, treatment and prevention. Rev Endocr Metab Disord. 2017;18(2):153–65.
28. Cho YS, Seo CH, Joo SY, Ohn SH. The association between vitamin D levels and burn factors in different burn types. Burns Trauma. 2020;8:tkaa018.
29. Muscogiuri G. Vitamin D: past, present and future perspectives in the prevention of chronic diseases. Eur J Clin Nutr. 2018;72(9):1221–5.
30. Holick MF. Vitamin D and health: evolution, biologic functions, and recommended dietary intakes for vitamin D. Clinic Rev Bone Miner Metab. 2009;7:2–19.
31. Uppala S, Sanguankeo A, Permpalung N. Significant association between vitamin D deficiency and sepsis: a systematic review and meta-analysis. BMC Anesthesiol. 2015;15:84.
32. Watkins RR, Yamshchikov AV, Lemonovich TL, Salata RA. The role of vitamin D deficiency in sepsis and potential therapeutic implications. J Infect. 2011;63(5):321–6.
33. Kemperk JA, Panwar B, Judd SE, Jenny NS, Wang HE, Gutiérrez OM. Plasma 25-hydroxyvitamin D and the longitudinal risk of sepsis in the REGARDS cohort. Clin Infect Dis. 2019;68(11):1926–31.
34. Yoo JW, Jung YK, Joo S, Lee SJ, Cho YJ, Jeong YY, et al. Serum vitamin D binding protein level, but not serum total, bioavailable, free vitamin D, is higher in 30-days survivors than in nonsurvivors with sepsis. Medicine (Baltimore). 2020;99(25):e20756.
35. Nguyen HB, Esthete B, Lau KH, Sai A, Villarin M, Baylink D. Serum 1,25-dihydroxyvitamin D: an outcome prognosticator in human sepsis. PLoS ONE. 2013;8(5):e6348.
36. Antoniades CG, Berry PA, Bruce M, Cross TJ, Portal AJ, Hussain MJ, et al. Actin-free Gc globulin: a rapidly assessed biomarker of organ dysfunction in acute liver failure and cirrhosis. Liver Transpl. 2007;13(9):1254–61.
37. Huang CZ, Zhang J, Zhang L, Yu CH, Mo Y, Mo LY. Serum vitamin D and vitamin-D-binding protein levels in children with chronic hepatitis B. World J Gastroenterol. 2021;27(3):253–66.
38. Ho AS, Cheng CC, Lee SC, Liu ML, Lee JY, Wang WM, et al. Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI. J Biomed Sci. 2010;17(1):58.
39. Triantos C, Kalafateli M, Ageletopoulou I, Diamantopoulou G, Spantidea PI, Michalaki M, et al. Vitamin D-related immunomodulation in patients with liver cirrhosis. Eur J Gastroenterol Hepatol. 2020;32(7):867–76.
40. Schulte W, Bernhagen J, Bučala R. Cytokines in sepsis: potent immunoregulators and potential therapeutic targets: an updated view. Mediators Inflamm. 2013;2013:165974.
41. Galley HF. Oxidative stress and mitochondrial dysfunction in sepsis. Br J Anaesth. 2011;107(1):57–64.
42. Hsu DZ, Chen KT, Li YH, Chuang YC, Liu MY. Sesamol delays mortality and attenuates hepatic injury after cecal ligation and puncture in rats: role of oxidative stress. Shock. 2006;25(5):528–32.
43. Hotamisligil GS, Davis RJ. Cell signaling and stress responses. Cold Spring Harb Perspect Biol. 2016;8(10):a006072.
44. Kim EK, Choi EJ. Compromised MAPK signaling in human diseases: an update. Arch Toxicol. 2015;89(6):867–82.
45. Nakagawa H, Maeda S. Molecular mechanisms of liver injury and hepatocarcinogenesis: focusing on the role of stress-activated MAPK. Patholog Res Int. 2012;2012:172894.
46. Wang L, Liang Q, Lin A, Chen X, Wu Y, Zhang B, et al. Puerarin increases survival and protects against organ injury by suppressing NF-κB/JNK signaling in experimental sepsis. Front Pharmacol. 2020;11:560.
47. Li M, Zhao H, Wu J, Wang L, Wang J, Lv K, et al. Nobelenin protects against acute liver injury via targeting c-Jun N-terminal kinase (JNK)-induced apoptosis of hepatocytes. J Agric Food Chem. 2020;68(27):7112–20.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.